Precision BioSciences (DTIL)
Develops ARCUS-based in vivo gene-editing therapies.
Something off on this page? Send us feedback.
Develops ARCUS-based in vivo therapies, with PBGENE-HBV and PBGENE-DMD as lead clinical-stage programs. Its single operating segment focuses on therapeutics following the food-and-agriculture spin-out; Imugene holds global rights to azer-cel and conducts its clinical execution.
Built around the ARCUS gene-editing platform, the company discovers and develops in vivo therapies. Lead clinical-stage programs include PBGENE-HBV and PBGENE-DMD. These programs reflect the company’s narrowed in vivo therapeutic focus.
Operating as a single segment, it concentrates on therapeutic uses of ARCUS, including gene insertion, excision, and elimination. The platform derives from a natural homing endonuclease. Early platform work included crop plants such as corn, soybeans, and cotton.
The food-and-agriculture business was spun out as Elo Life Systems, while clinical execution of the azer-cel cancer program moved to Imugene. When the Prevail collaboration ended, programs returned for independent development or new partnerships.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 9, 2026 | Oppenheimer | Target | Target: — | Target: $20 |
| Mar 13, 2026 | Jefferies | Target | Target: — | Target: $19 |
| Jan 10, 2025 | BMO Capital | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $87.5M · Total debt $28.1M · Total assets $125.9M · Shareholders' equity $45.3M
- Revenue
- $0
- Operating income
- −$19.2M
- Net income
- −$32.7M
No dividends on record.
| Institutions | 64.47% | 17.79M shares | |
|---|---|---|---|
| 98 holders · as of Jun 30, 2026 | |||
| Insiders | 2.93% | 808.2K shares | |
| 12 holders · as of Aug 3, 2026 | |||
| Strategic holders | 7.75% | 2.14M shares | |
| 1 holder · as of Jan 27, 2026 | |||
| Other | 24.85% | 6.86M shares | |
| remainder | |||
27.60M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (27.60M in the company's Sep 22, 2026 report, 12.83M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Abrdn PLCInstitution | 8.08% | 2.23M | as of Jun 30, 2026 |
Aberdeen Group plcStrategic | 7.75% | 2.14M | filed Jan 27, 2026 |
Bleichroeder LPInstitution | 7.31% | 2.02M | as of Jun 30, 2026 |
Octagon Capital Advisors LPInstitution | 4.89% | 1.35M | as of Jun 30, 2026 |
Boothbay Fund Management, LLCInstitution | 4.88% | 1.35M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 18, 2026 | J. Jefferson Smith | officer: Chief Research Officer | −4,925 | $3.84 |
| Feb 18, 2026 | Dario Scimeca | officer: General Counsel and Secretary | −4,925 | $3.84 |
| Feb 18, 2026 | John Alexander Kelly | officer: Chief Financial Officer | −8,149 | $3.84 |
| Feb 18, 2026 | Michael Amoroso | director, officer: President and CEO | −20,559 | $3.84 |
| Jan 21, 2026 | J. Jefferson Smith | officer: Chief Research Officer | −10,200 | $4.03 |
- Sarepta Therapeutics
DMD genetic-medicine rivalry through ELEVIDYS
- Intellia Therapeutics
In vivo CRISPR liver editing with late-stage programs
- CRISPR Therapeutics
LNP-enabled in vivo liver gene-editing programs
- Dyne Therapeutics
DMD rivalry through exon-skipping therapies
- Editas Medicine
In vivo CRISPR development for one-time therapies
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Precision BioSciences | $7.07 | +8.69% | $83.4M | — | — | 1.9 | −100.0% |
| Sarepta Therapeutics | $20.78 | +3.18% | $2.13B | — | 36.1 | 1.1 | −34.3% |
| Intellia Therapeutics | $12.58 | +2.93% | $1.71B | — | — | 28.7 | −46.2% |
| CRISPR Therapeutics | $58.85 | +0.88% | $5.63B | — | — | 420.1 | +1,041.4% |
| Dyne Therapeutics | $17.43 | +1.81% | $3.20B | — | — | — | — |
| Editas Medicine | $2.86 | +1.14% | $434.3M | — | — | 9.2 | +232.3% |
| Median | — | 36.1 | 19.0 | +99.0% |